ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023
A Pilot Study of
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03809078 (A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Prospective evaluation of the PRIMARY score using [European journal of nuclear medicine and molecular imaging · 2026Article
- GRPR-Targeted Radionuclide Conjugates: A Molecular Evolution Perspective.Chemistry & biodiversity · 2026Review
- Prospective head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2026Article
- Diagnostic performance of gastrin-releasing peptide receptor-targeted positron-emission tomography in biochemically recurrent prostate cancer-a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2026Article
- Exploration of a novel quantitative model based on PRIMARY score in the diagnosis of clinically significant prostate cancer using [18F]PSMA PET/CT.World journal of urology · 2025Article
- The evolving role of positron emission tomography in precision prostate cancer biopsy.European journal of clinical investigation · 2025Review
- Tackling Prostate Cancer with Theranostic E5B9-Bombesin Target Modules (TMs): From Imaging to Treatment with UniCAR T-Cells.International journal of molecular sciences · 2025Article
- Article
- Accuracy of combined multi-parametric MRI and PSMA PET-CT in diagnosing localized prostate cancer: newer horizons for a biopsy-free pathway.European journal of hybrid imaging · 2023Article
- Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET.European journal of nuclear medicine and molecular imaging · 2023Article
- The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeting of lesions seen on multiparametric MRI (mpMRI) improves prostate cancer (PC) detection at biopsy. However, 20%-65% of highly suspicious lesions on mpMRI (PI-RADS [Prostate Imaging-Reporting and Data System] 4 or 5) are false-positives (FPs), while 5%-10% of clinically significant PC (csPC) are missed. Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptors (GRPRs) are both overexpressed in PC. We therefore aimed to evaluate the potential of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.